{"title":"Therapeutic Effect of Resveratrol and Gamma-GlutamylCysteine in Azathioprine Drug-Induced Hepatotoxicity","authors":"Huda Sultan Almutairi, M. Tashkandi, J. Yousef","doi":"10.51847/wp8c0lisjp","DOIUrl":null,"url":null,"abstract":"The purpose of the current literature is to examine the protective properties of resveratrol (RSV) and gamma-glutamylcysteine (γ-GC) against hepatic injury induced by Azathioprine (AZA) that may have a favorable impact on using resveratrol and/ or gamma-glutamylcysteine with immunosuppressant drugs therapy. The study duration was 4 weeks; fifty Male Wister Albino Rats were classified into 5 groups: control group: and rats were orally treated with normal saline. AZA group, Rats were taken AZA orally at 10 mg/kg. RSV group, rats had oral administration of AZA along with IP injection of RSV; 8ml/Kg, GC group, rats had oral administration of AZA and γ-GC; 100mg/Kg, combination group, rats had oral administration of AZA with IP injection of RSV; 8ml/Kg and γ-GC; 100mg/Kg after 2 h post-injection for 4 weeks. The results indicate that AZA treatment increases alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, decreases antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) and depleted hepatic microRNA-122 (miR-122) referred to hepatic injury. Administration of RSV/ γ-GC separately or together modulates levels of liver enzymes and protective hepatic tissue. γ-GC reduced the degree of histological hepatic damage in rats. The results reveal that co-administration of RSV and/or γ-GC can reduce immunosuppressant drug hepatotoxicity.","PeriodicalId":8308,"journal":{"name":"Archives Of Pharmacy Practice","volume":null,"pages":null},"PeriodicalIF":0.6000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives Of Pharmacy Practice","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.51847/wp8c0lisjp","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The purpose of the current literature is to examine the protective properties of resveratrol (RSV) and gamma-glutamylcysteine (γ-GC) against hepatic injury induced by Azathioprine (AZA) that may have a favorable impact on using resveratrol and/ or gamma-glutamylcysteine with immunosuppressant drugs therapy. The study duration was 4 weeks; fifty Male Wister Albino Rats were classified into 5 groups: control group: and rats were orally treated with normal saline. AZA group, Rats were taken AZA orally at 10 mg/kg. RSV group, rats had oral administration of AZA along with IP injection of RSV; 8ml/Kg, GC group, rats had oral administration of AZA and γ-GC; 100mg/Kg, combination group, rats had oral administration of AZA with IP injection of RSV; 8ml/Kg and γ-GC; 100mg/Kg after 2 h post-injection for 4 weeks. The results indicate that AZA treatment increases alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels, decreases antioxidant enzymes catalase (CAT) and superoxide dismutase (SOD) and depleted hepatic microRNA-122 (miR-122) referred to hepatic injury. Administration of RSV/ γ-GC separately or together modulates levels of liver enzymes and protective hepatic tissue. γ-GC reduced the degree of histological hepatic damage in rats. The results reveal that co-administration of RSV and/or γ-GC can reduce immunosuppressant drug hepatotoxicity.
期刊介绍:
The journal will cover technical and clinical studies related to health, ethical and social issues in field of Pharmacy Practice, Clinical Pharmacy, Social and administrative pharmacy, Hospital pharmacy, Pharmaceutical technology, Pharmaceutical chemistry, Pharmaceutical analysis, Behavioral medicines, Statistical methods in Pharmacy, Public health in pharmacy, health communication, communication skills, counseling, community pharmacy practice, Pharmacy management, pharmacoecnomics, pharmaceutical care, evidence base medicines, therapeutics, pharmacology, organ medicines, Pharmacy education etc . Articles with clinical interest and implications will be given preference.